Subscribe To
Anaptys announces participation in november investor conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...
November 1, 2023, 9:15 am
Anaptys to present phase 1 data on anb032, its btla agonist antibody, at the 32nd eadv congress
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...
October 11, 2023, 9:15 am
anaptysbio's skin disease drug meets main goal in late-stage study
anaptysbio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main g...
October 9, 2023, 8:32 am
anaptysbio to present at the stifel 2023 immunology and inflammation virtual summit
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotech...
September 12, 2023, 9:15 am
anaptysbio- and gsk-partnered immuno-oncology agent jemperli (dostarlimab-gxly) plus chemotherapy approved in the u.s. for dmmr/msi-h primary advanced or recurrent endometrial cancer
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Fo...
July 31, 2023, 5:34 pm
anaptysbio: despite early successes, current situation does not impress
anaptysbio, Inc. had major deals with big pharma in past years. However, its current programs are not t...
July 7, 2023, 10:33 am
anaptysbio announces participation in upcoming investor conferences
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...
May 30, 2023, 8:15 pm
anaptysbio, inc. (anab) reports q1 loss, misses revenue estimates
anaptysbio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Es...
May 11, 2023, 7:02 pm
anaptysbio: upside could be lying ahead very nicely
US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and tak...
March 30, 2023, 11:44 pm
anaptysbio to participate in upcoming november investor conferences
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...
November 9, 2022, 2:10 pm
anaptysbio, inc. (anab) reports q3 loss, misses revenue estimates
anaptysbio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, ...
November 8, 2022, 7:33 pm
anaptysbio, inc. (anab) soars 6.2%: is further upside left in the stock?
anaptysbio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest ...
April 26, 2022, 8:17 am
anaptysbio to discontinue imsidolimab development in moderate-to-severe acne
anaptysbio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did no...
March 15, 2022, 8:22 am